Nicotinamide Riboside Benefits: What Human Trials Show

Nicotinamide riboside benefits are best established for changing blood NAD+ biomarkers. Human studies have also investigated walking performance, cardiovascular physiology, cognition, fatigue and metabolic health. The results vary considerably, and recent trials make a simple list of “proven anti-aging benefits” misleading. ^{[1] [2] [3]}

This review separates what NR changes in a laboratory measurement from what it improves in a person's life. It also distinguishes NR alone from NR plus exercise, NR with resveratrol or pterostilbene, and multi-ingredient metabolic formulas. Those distinctions are essential when deciding what a supplement might reasonably deliver.

Four different meanings of a benefit

A biomarker effect means a measured quantity changed: for example, whole-blood NAD+. A physiological effect might involve blood flow or cellular respiration. A functional effect concerns something a person can do, such as walking farther. A clinical outcome concerns disease progression, hospitalization or survival.

These levels are related, but one does not automatically establish the next. A biological rationale justifies a trial; a favorable trial on the intended outcome justifies the corresponding claim. It is possible for NR to raise NAD+ substantially while producing no detectable improvement in the clinical endpoint.

That is exactly why the null studies are useful. They test whether target engagement is sufficient in a particular setting, rather than questioning whether the molecule exists or enters metabolism.

Human evidence at a glance

These are publications with different designs, not interchangeable votes in favor of NR. See the individual reports for denominators, attrition and analysis populations. ^{[1] [4] [5] [6] [7] [3] [2]}

The most consistent effect: blood NAD+ rises

In the 140-person trial, 35 participants were randomized to each of four groups: placebo or one of three NR doses. At two weeks, reported whole-blood NAD+ increases were about 22%, 51% and 142% with 100, 300 and 1,000 mg/day, respectively. Adverse-event reporting did not differ significantly between NR and placebo over the eight-week study. ^[1]

That is useful evidence that oral NR can influence the NAD metabolome. It does not establish a dose-response relationship for memory, fatigue or longevity. A larger biomarker increase is not necessarily a larger benefit, and a percentage change is sensitive to the person's baseline, laboratory method and sampling conditions.

There is also no validated universal “optimal NAD+ number” that can be used to titrate healthy adults indefinitely. A 2026 seven-cohort analysis found whole-blood NAD+ comparatively stable across age and lifestyle while responsive to NR. That observation argues against treating a higher reading as an automatic reversal of biological age. ^[8]

Walking performance and peripheral artery disease

NICE PAD is among the more clinically relevant positive signals because walking capacity matters to patients. The trial randomized 90 people with peripheral artery disease to placebo, NR, or NR plus resveratrol for six months. The NR-alone comparison produced a reported approximately 17.6-meter advantage in six-minute walking distance over placebo. ^[4]

The statistical context matters. The study used a prespecified one-sided approach and 90% confidence interval; the reported P value was .08. It should not be retold as an ordinary two-sided P<.05 finding or a guarantee of improved circulation in otherwise healthy supplement users. Resveratrol did not add a clear walking benefit.

The correction notice restored an omitted registration sentence; it did not introduce a second trial or a new patient cohort. Count the original study once. ^[9]

For someone with PAD, this is a reason for further research and a specific clinical discussion. It does not replace smoking cessation, appropriate exercise, vascular evaluation or established medical care. For someone without PAD, the result is not a general estimate of how much farther NR will allow them to walk.

Heart health and blood pressure

The small heart-failure trial found that NR was generally tolerated and approximately doubled whole-blood NAD+. Changes correlated with selected immune-cell respiratory and inflammatory measures. Those findings help establish feasibility and biological activity. With 30 participants and a safety-focused design, the trial cannot establish improved survival, fewer hospitalizations or a meaningful increase in heart pumping function. ^[5]

A separate six-week trial in older adults compared NR plus walking exercise with placebo plus exercise, alongside an NR-only group. NR did not improve the primary daytime systolic-blood-pressure outcome over the exercise comparator. Post hoc nighttime-pressure findings in selected participants were exploratory. They do not justify calling NR a proven blood-pressure treatment. ^[6]

A claim about “heart cellular energy” therefore needs careful translation. The mechanism may be plausible while the clinical effect remains unproven. Avoid stopping effective cardiovascular treatment because a supplement marketing page uses the same biological vocabulary.

Energy, fatigue, sleep and long COVID

“More cellular energy” is not a standardized clinical endpoint. ATP biology, perceived energy, exercise capacity, sleep quality and disease-related fatigue are different measurements. An intervention can alter the first without improving the others.

The randomized long-COVID study is particularly relevant to symptom claims. Among 58 participants in a delayed-start protocol, NR increased blood NAD+ but did not improve cognition, fatigue, sleep or mood versus placebo. Substantial differential dropout and exploratory within-group analyses further limit favorable interpretations. ^[7]

If a group improves from its own baseline, that change can reflect natural recovery, regression to the mean, expectation, concurrent care or other factors. The randomized comparison is designed to account for those influences. Reporting only the within-group improvement gives readers an exaggerated estimate of the supplement's contribution.

Persistent fatigue also deserves an appropriate assessment. An NR trial should not delay investigation of sleep disorders, medication effects, anemia or other clinically relevant causes. The evidence does not support using the phrase “NAD depletion” as a universal diagnosis for unexplained exhaustion.

Muscle, exercise and physical performance

Changes in muscle metabolites are scientifically interesting but are different from improved strength, endurance or mitochondrial respiratory capacity. Small studies often measure many outcomes; an isolated favorable result should be weighed against the primary outcomes and the number of comparisons.

The 2026 Friedreich's ataxia factorial trial enrolled 66 people, including adults and children, and studied NR with or without individualized exercise. The combination improved peak oxygen uptake relative to the no-exercise placebo condition, but did not outperform exercise alone. NR alone did not meet the efficacy threshold. ^[10]

That is an important comparator lesson: a successful combination does not prove that every ingredient adds benefit. The findings also concern a specific genetic disorder and supervised intervention, not ordinary gym performance or a pediatric supplement regimen.

Our metabolic and weight-loss review examines the obesity and muscle companion papers without counting the same participants twice.

Brain health, memory and Alzheimer's disease

Early studies and animal models made brain NAD+ an attractive target. The clinical distinction remains whether a person thinks or functions better, not simply whether a biomarker moves.

The 2026 MCI trial randomized 52 people; 49 started treatment and 42 completed it. After 12 weeks of 1,000 mg/day, blood NAD+ approximately doubled, but cognition, total cerebral blood flow and blood pressure did not improve. Exploratory regional perfusion signals require confirmation. ^[3]

Earlier small MCI work also failed to establish cognitive improvement, despite biological and exploratory findings. A separate crossover study reported a plasma pTau217 signal without improvement in its primary cognitive assessment. Neither result establishes prevention or slowed progression of Alzheimer's disease. ^{[11] [12]}

The brain-health dossier explains the trial sequence, analysis denominators and why combination formulas cannot be credited to NR alone.

Parkinson's disease: why the later trial matters

NADPARK established early target engagement in a small phase I study. NR-SAFE added short-term high-dose safety information. Those were worthwhile steps in a research program; they were not definitive disease-modification trials. ^{[13] [14]}

The 2026 phase III NOPARK trial then randomized 410 people for 52 weeks. The primary analysis included 393. NR did not slow disease progression, and the adjusted MDS-UPDRS I–III difference was 2.72 points in favor of placebo. The difference was below the stated clinically important threshold, but its direction does not support presenting NR as a successful Parkinson's treatment. ^[2]

The Parkinson's review puts these studies in chronological and evidential context. Increasing the dose without evidence is not an established solution to the phase III result.

Skin, hair, fertility, glaucoma and kidney claims

These topics need molecule- and outcome-specific evidence. A mouse experiment involving tissue repair cannot establish visible skin rejuvenation in people. Evidence for nicotinamide in skin-cancer prevention is evidence for another B3 compound, not for NR. Likewise, reproductive experiments do not demonstrate better human pregnancy or live-birth outcomes from an NR supplement.

Glaucoma, kidney disease and related conditions are active research areas, but a registry entry is a plan rather than a published result. A biomarker or pilot study should not be promoted as proven preservation of vision or kidney function. Patients in these settings may also have medicines and safety considerations that differ from those of healthy volunteers.

For a proposed claim, ask for the exact paper, compound, participants, endpoint and comparator. If those cannot be specified, the claim is not made more credible by appearing in a long list of organ systems.

Does NR extend life or reverse aging?

Human lifespan extension has not been established. Neither a rise in blood NAD+ nor an exploratory change in an epigenetic measure proves that a person will live longer, remain disease-free longer or become biologically younger by a stated number of years.

A useful longevity claim would need an outcome capable of supporting it, appropriate follow-up and replication. Short safety and target-engagement studies are not designed to answer that question. The absence of a lifespan result does not negate the biomarker research; it defines what that research can legitimately tell us.

How long should benefits take?

Blood biomarker changes can appear within days to weeks in pharmacokinetic and dose-response studies. That does not establish a deadline for a subjective energy effect or a reason to keep increasing intake until something is felt. ^{[15] [1]}

Before-and-after photos, testimonials and Reddit accounts can identify experiences worth studying. They cannot control for changes in diet, exercise, sleep, expectations or other supplements. A report that “I felt nothing” also does not prove the absence of a biochemical response. Both types of anecdote answer a different question from a controlled trial.

A more useful personal decision defines the intended outcome, any relevant baseline assessment, tolerability and a reassessment point with appropriate clinical advice. If there is no meaningful change, a higher NAD+ laboratory value alone may not justify continuing indefinitely.

What this means when buying NR

Choose a clearly identified product only after deciding whether the intended goal fits the evidence. More ingredients, a higher number on the label or a larger absorption claim cannot compensate for an unproven clinical outcome. The dosage guide, safety review and buying comparison address those separate decisions.

The NR Data Center links each study to its own findings and limitations. Use it to judge the specific benefit being proposed, rather than relying on the total number of papers mentioning NR.